N4 Pharma announces pre-clinical development of an oral RNA IBD treatment using Nuvec: N4 101
Dec.06, 2024 in
News
N4 Pharma Plc the specialist preclinical stage biotech company announces a new lead programme, N4 101. This orally-delivered inflammation inhibitor for Irritable Bowel Disease (IBD) uses Nuvec®, the company’s novel silica non-viral, non-lipid nanoparticle delivery system, to overcome the challenges with current IBD treatments.
Comments Off on N4 Pharma announces pre-clinical development of an oral RNA IBD treatment using Nuvec: N4 101